{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:59:54Z","timestamp":1787702394233,"version":"build-2784847793"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1097\/fpc.0000000000000018","type":"journal-article","created":{"date-parts":[[2013,11,21]],"date-time":"2013-11-21T09:18:46Z","timestamp":1385025526000},"page":"43-51","source":"Crossref","is-referenced-by-count":49,"title":["The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study"],"prefix":"10.1097","volume":"24","author":[{"given":"Catherine E.","family":"de Keyser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas J.M.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthijs L.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loes E.","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 G.","family":"Uitterlinden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf H.","family":"Klungel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Verstuyft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke-Hilse","family":"Maitland-van der Zee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno H.","family":"Stricker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R5-6-20210213","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0022-2275(20)41379-3","article-title":"The discovery and development of HMG-CoA reductase inhibitors.","volume":"33","author":"Endo","year":"1992","journal-title":"J Lipid Res"},{"key":"R7-6-20210213","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"R8-6-20210213","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin-associated myopathy.","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"key":"R9-6-20210213","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/MOL.0b013e328235a5a2","article-title":"Pharmacogenomics of statin response.","volume":"18","author":"Mangravite","year":"2007","journal-title":"Curr Opin Lipidol"},{"key":"R10-6-20210213","first-page":"555","article-title":"Pharmacogenomics of statin response.","volume":"10","author":"Mangravite","year":"2008","journal-title":"Curr Opin Mol Ther"},{"key":"R12-6-20210213","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/pr.110.002857","article-title":"Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake.","volume":"63","author":"Niemi","year":"2011","journal-title":"Pharmacol Rev"},{"key":"R13-6-20210213","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/01.fpc.0000170913.73780.5f","article-title":"Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B15, SLCO1B115 and SLCO1B115C1007G, by using transient expression systems of HeLa and HEK293 cells.","volume":"15","author":"Kameyama","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"R14-6-20210213","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2217\/14622416.8.7.787","article-title":"Role of OATP transporters in the disposition of drugs.","volume":"8","author":"Niemi","year":"2007","journal-title":"Pharmacogenomics"},{"key":"R15-6-20210213","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","article-title":"Impact of OATP transporters on pharmacokinetics.","volume":"158","author":"Kalliokoski","year":"2009","journal-title":"Br J Pharmacol"},{"key":"R16-6-20210213","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/gm120","article-title":"Pharmacogenomic insights into treatment and management of statin-induced myopathy.","volume":"1","author":"Peters","year":"2009","journal-title":"Genome Med"},{"key":"R17-6-20210213","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/01.fpc.0000230416.82349.90","article-title":"SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.","volume":"16","author":"Pasanen","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"R18-6-20210213","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s00210-006-0040-y","article-title":"Pharmacogenomics of human OATP transporters.","volume":"372","author":"Konig","year":"2006","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"R19-6-20210213","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy - a genomewide study.","volume":"359","author":"Link","year":"2008","journal-title":"N Engl J Med"},{"key":"R20-6-20210213","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/clpt.2009.197","article-title":"Transporter pharmacogenetics and statin toxicity.","volume":"87","author":"Niemi","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"R22-6-20210213","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/BF00145007","article-title":"Determinants of disease and disability in the elderly: the Rotterdam Elderly Study.","volume":"7","author":"Hofman","year":"1991","journal-title":"Eur J Epidemiol"},{"key":"R24-6-20210213","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/pds.1866","article-title":"Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy.","volume":"19","author":"Becker","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R25-6-20210213","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","article-title":"A simple salting out procedure for extracting DNA from human nucleated cells.","volume":"16","author":"Miller","year":"1988","journal-title":"Nucleic Acids Res"},{"key":"R34-6-20210213","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clpt.2006.06.010","article-title":"SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.","volume":"80","author":"Niemi","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"R36-6-20210213","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1067\/mcp.2002.128388","article-title":"Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein.","volume":"72","author":"Cummins","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"R37-6-20210213","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications.","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"R38-6-20210213","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.clpt.6100226","article-title":"The current state of knowledge on age, sex, and their interactions on clinical pharmacology.","volume":"82","author":"Schwartz","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R39-6-20210213","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/03602530902722679","article-title":"Pharmacokinetics and drug metabolism in the elderly.","volume":"41","author":"Klotz","year":"2009","journal-title":"Drug Metab Rev"},{"key":"R40-6-20210213","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1124\/jpet.103.061234","article-title":"The effect of age on P-glycoprotein expression and function in the Fischer-344 rat.","volume":"309","author":"Warrington","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"R41-6-20210213","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/eurheartj\/ehl391","article-title":"Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40: a cohort study.","volume":"28","author":"Penning-van Beest","year":"2007","journal-title":"Eur Heart J"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:21:45Z","timestamp":1620951705000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201401000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000018","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}